Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with a RMB 1.1 billion outlay to establish a new antibody drug conjugate (ADC) manufacturing plant in Zhangjiang, located in Shanghai’s Pudong New Area. This strategic move by the firm is aimed at addressing the escalating demand for tumor treatment products in the region.
Meeting the Growing Demand for Tumor Treatments
The rationale behind Daiichi Sankyo’s substantial investment in the new ADC manufacturing plant is to cater to the growing demand for tumor products. By expanding its production capabilities in China, the company is positioning itself to better serve the local market and contribute to the global supply chain of advanced cancer treatments.
Enhancing Local Production Capabilities
The establishment of the new manufacturing plant in Shanghai’s Pudong New Area will not only enhance Daiichi Sankyo’s local production capabilities but also strengthen its presence in the Chinese market. This investment reflects the company’s commitment to innovation and its dedication to improving access to life-saving medications for patients in China and beyond.-Fineline Info & Tech
